Milestone Triggers $10 Million Payment to Molecular Templates

Austin, TX (Press Release) – Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery and devel­op­ment of the com­pany’s pro­pri­e­tary engi­neered toxin bodies (ETBs), which are dif­fer­en­ti­ated, targeted, biologic thera­peutics for cancer and other serious dis­eases, today announced the initiation of dosing in a Phase I study investigating TAK-169 in patients with re­lapsed / re­frac­tory multiple myeloma. Co-developed with Takeda Pharma­ceu­tical Com­pany Limited (“Takeda”), TAK-169 is a poten­tial first-in-class CD38-targeting ETB. As a result of achieving this mile­stone, MTEM will re­ceive a $10 million pay­ment …

• TAK-169 Represents a Novel Mechanism of Action Targeting CD38
• Phase I Study to be Conducted in Relapsed/Refractory Multiple Myeloma Patients

Austin, TX (Press Release) – Molecular Templates, Inc., (Nasdaq: MTEM, “Molec­u­lar,” “Molec­u­lar Templates” or “MTEM”) a clin­i­cal stage bio­pharma­ceu­tical com­pany focused on the discovery and devel­op­ment of Engi­neered Toxin Bodies (ETBs), a new class of targeted biologic ther­a­pies that possess unique mech­a­nisms of action in on­col­ogy, announced that the U.S. Food and Drug Admin­istra­tion (FDA) has accepted the Inves­ti­ga­tional New Drug (IND) appli­ca­tion for TAK-169, an ETB targeting CD38.

MTEM and partner Takeda Pharma­ceu­tical Company Limited (Takeda) are co-developing TAK-169 and plan to conduct an open …

The Agreement Will Support the Development of a Potential New Treatment Option for Multiple Myeloma

Austin, TX (Press Release) – Molecular Templates, Inc. (Nasdaq:MTEM) today announced an agree­ment with Takeda Pharma­ceu­tical Company Limited (Takeda) for the joint devel­op­ment of CD38-targeted engi­neered toxin bodies (ETBs) for the treat­ment of patients with diseases such as multiple myeloma. The lead devel­op­ment can­di­date is a CD38-targeted ETB that resulted from a pre­vi­ous discovery col­lab­o­ration be­tween the two com­pa­nies.

The parties devel­oped pre­clin­i­cal stage ETBs targeting CD38 under the prior discovery col­lab­o­ration. Takeda and Molecular Templates will further develop the ETBs for the treat­ment of multiple myeloma under this new license, devel­op­ment and …